tbuckley/cabot-search huggingface dataset:
Treatment Practices and Outcomes in Older Adults with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in the Veterans Health Administration
Authors: Ahmad S Halwani, Kelli M Rasmussen, Vikas Patil, Catherine Li, Christina Young, Zachary Burningham, Mathias Schulz, Jia Li, Anthony Masaquel, Mary Halloran, Elisha Delong-Sieg, Brian C Sauer
Journal: Blood (2018)
Antibiotics for Acne—A Pilot Study of Collateral Damage to the Skin Microbiome
Authors: Tiffany C. Scharschmidt
Journal: JAMA Dermatology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
DNA methylation signature predictive of benefit from neoadjuvant chemotherapy in esophageal adenocarcinoma: Results from the MRC OEO2 phase III trial.
Authors: Raghav Sundar, Alvin Ng, Hermioni Zouridis, Taotao Sheng, Shenli Zhang, Ming Hui Lee, Nisha Padmanabhan, Wen Fong Ooi, Aditi Qamra, Matthew Guy Nankivell, Ruth E. Langley, William H. Allum, David Cunningham, Heike I Grabsch, Patrick Tan
Journal: Journal of Clinical Oncology (2019)

43 Background: Platinum and 5-Fluorouracil (5FU) neoadjuvant chemotherapy followed by surgery is one of the standard approaches for patients with resectable EAC. To date, there are no predictive biomarkers of chemotherapy benefit. We hypothesize that DNA methylation of genes in key biologic and oncogenic pathways predict for chemotherapy benefit in EAC. Methods: In the OE02 trial, 802 patients with resectable esophageal carcinoma were randomised to surgery alone (S) versus two cycles of cisplatin and 5FU chemotherapy followed by surgery (CS). DNA was extracted from 213 EAC resection specimens (110 from the (CS) arm, 103 from the (S) arm). DNA methylation was analyzed at 1505 CpG sites within 807 genes using the Illumina GoldenGate platform. Cox proportional hazard analysis was performed to identify predictive markers of survival in (CS) arm; non-negative matrix factorization (NMF) was used to delineate methylation signatures. Results: Methylation status of 1505 CpG sites had no statistical difference between the (CS) and (S) arms. In the (CS) arm, 87 (5.7%) CpG sites were initially identified as promising candidates in univariate analysis (p &lt; 0.05 cutoff). NMF generated a 4 CpG site signature which divided patients into poor risk and good risk. Genes involved in the signature include RUNX1T1, CCND2, MST1R and MMP14. Survival was significantly different between poor risk and good risk in (CS) arm (HR 0.32, 95% CI: 0.21 to 0.52, p &lt; 0.0001). No difference in survival was detected in the surgery arm (HR 1.12, 95% CI: 0.76 to 1.80, p = 0.48), suggesting the signature served as a predictive and not prognostic biomarker. Methylation signature remained an independent predictor of survival in multivariate analysis with clinicopathologic factors (along with age and vascular invasion). Conclusions: Chemotherapy does not appear to change methylation status of EAC. Hypermethylation of RUNX1T1, CCND2 and hypomethylation of MST1R and MMP14 leads to significantly decreased benefit from chemotherapy in EA. We describe an epigenetic signature which may serve as a predictive biomarker for chemotherapy benefit using data form the largest bank of DNA methylation in EA reported to date.
Response to: ‘When binary and continuous responses disagree’ by Dr Ouyang
Authors: Kim Lauper, Delphine Sophie Courvoisier, Cem Gabay
Journal: Annals of the Rheumatic Diseases (2019)

We thank Dr Ouyang for his comment on our work. 1e fully agree that patients stop treatment based, in part, on a lack of satisfactory clinical response.Thus, examining disease activity during follow-up, for instance at 1 year, will be influenced by attrition bias.If patients mostly stop the drug due to inefficacy, comparing only the patients who remain on treatment may lead to the tautological finding that for the people remaining on treatment, the drug is effective.Another potential explanation for the dissociation between drug retention and other measures of effectiveness could be related to the fact that patients treated with tocilizumab had more previous therapies than patients treated with tumour necrosis factor (TNF) inhibitors. 2 It is therefore plausible that the lack of other treatment alternatives may influence patients and physicians to keep a less effective treatment.In addition to ineffectiveness, patients stop their treatment for many other reasons, which are unfortunately not always well documented.In our study, half of the patients in each group stopped for 'other reasons' than effectiveness or adverse events, which may include a combination of reasons.We thus cannot assert the exact motive of drug discontinuation for most patients, which prevented us to draw any conclusion regarding differences between groups.Moreover, one treatment could be more effective than the other, and even if we were to consider only patients who remained under therapy, we could still detect some differences in degree of efficacy.Though the LUNDEX 3 is a solution to account in part for attrition bias, we agree with Dr Ouyang that it is incomplete because it supposes that all patients stopped for ineffectiveness, which may underestimate true effectiveness, and because it does not take into account difference in baseline characteristics.In addition, it does not allow directly statistical hypothesis testing to determine whether a difference is significant or not.In our opinion, new methods and recommendations are thus dearly needed for comparative effectiveness research.Points to consider on this particular subject are currently being developed by a European League Against Rheumatism task force, in which we are actively taking part.We hope that the results of this initiative will help researchers to navigate between the different methods available and improve the quality of future studies.Regarding Disease Activity Score 28 joints (DAS28) evolution, we found that DAS28 decreased more with tocilizumab as monotherapy and in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARD) than with TNF inhibitors, but this was statistically significant only for tocilizumab in combination with csDMARDs compared with TNF inhibitors in combination with csDMARDs (coefficient 0.44, p=0.04).As discussed in our article, this is consistent with tocilizumab's greater effect on acute-phase reactants.
Association study in African-admixed populations across the Americas recapitulates asthma risk loci in non-African populations
Authors: Michelle Daya, Nicholas M. Rafaels, Tonya M. Brunetti, Sameer Chavan, Albert M. Levin, Aniket Shetty, Cristopher R. Gignoux, Meher Preethi Boorgula, Genevieve Wojcik, Monica Campbell, Candelaria I. Vergara, Dara G. Torgerson, Victor E. Ortega, Ayo Doumatey, Henry R. Johnston, Nathalie Acevedo, Maria A. Araujo, Pedro C. Avila, Gillian Belbin, Eugene R. Bleecker, Carlos Bustamante, Luis Caraballo, Alvaro A. Cruz, Georgia M. Dunston, Celeste Eng, Mezbah U. Faruque, Trevor S. Ferguson, Camila Figueiredo, Jean G. Ford, Weiniu Gan, Pierre-Antoine Gourraud, Nadia Hansel, Ryan D. Hernandez, Edwin P. Herrera-Paz, Silvia Jimenez, Eimear E. Kenny, Jennifer Knight-Madden, Rajesh Kumar, Leslie E. Lange, Ethan M. Lange, Antoine Lizee, Pissamai Maul, Trevor Maul, Alvaro J. Mayorga Sirera, Deborah A. Meyers, Dan L. Nicolae, Timothy D O'Connor, Ricardo R. Oliveira, Christopher O. Olopade, Olufunmilayo Olopade, Zhaohui S. Qin, Charles Rotimi, Nicolas Vince, Harold Watson, Rainford J. Wilks, James G. Wilson, Steven Salzberg, Carole Ober, Esteban G. Burchard, L. Keoki Williams, Terri H. Beaty, Margaret A. Taub, Ingo Ruczinski, Rasika A. Mathias, Kathleen C. Barnes
Journal: Journal of Allergy and Clinical Immunology (2019)
Tumor Suppressor miRNA-204-5p Regulates Growth, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer
Authors: Bok Sil Hong, Han Suk Ryu, Namshin Kim, Jisun Kim, Eunshin Lee, Hyunhye Moon, Kyoung Hyoun Kim, Min-Sun Jin, Nam Hoon Kwon, Sunghoon Kim, Donghyun Kim, Doo Hyun Chung, Kyeonghun Jeong, Kwangsoo Kim, Ki Yoon Kim, Han-Byoel Lee, Wonshik Han, Jihui Yun, Jong-Il Kim, Dong-Young Noh, Hyeong-Gon Moon
Journal: Cancer Research (2019)

Various miRNAs play critical roles in the development and progression of solid tumors. In this study, we describe the role of miR-204-5p in limiting growth and progression of breast cancer. In breast cancer tissues, miR-204-5p was significantly downregulated compared with normal breast tissues, and its expression levels were associated with increased survival outcome in patients with breast cancer. Overexpression of miR-204-5p inhibited viability, proliferation, and migration capacity in human and murine breast cancer cells. In addition, miR-204-5p overexpression resulted in a significant alteration in metabolic properties of cancer cells and suppression of tumor growth and metastasis in mouse breast cancer models. The association between miR-204-5p expression and clinical outcomes of patients with breast cancer showed a nonlinear pattern that was reproduced in experimental assays of cancer cell behavior and metastatic capacities. Transcriptome and proteomic analysis revealed that various cancer-related pathways including PI3K/Akt and tumor-immune interactions were significantly associated with miR-204-5p expression. PIK3CB, a major regulator of PI3K/Akt pathway, was a direct target for miR-204-5p, and the association between PIK3CB-related PI3K/Akt signaling and miR-204-5p was most evident in the basal subtype. The sensitivity of breast cancer cells to various anticancer drugs including PIK3CB inhibitors was significantly affected by miR-204-5p expression. In addition, miR-204-5p regulated expression of key cytokines in tumor cells and reprogrammed the immune microenvironment by shifting myeloid and lymphocyte populations. These data demonstrate both cell-autonomous and non-cell-autonomous impacts of tumor suppressor miR-204-5p in breast cancer progression and metastasis. SIGNIFICANCE: This study demonstrates that regulation of PI3K/Akt signaling by miR-204-5p suppresses tumor metastasis and immune cell reprogramming in breast cancer.
Changing Times in Liver Transplantation for Alcohol-Associated Liver Disease
Authors: Mack C. Mitchell, Willis C. Maddrey
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Serial effects are optimal
Authors: Guido Marco Cicchini, David C. Burr
Journal: Behavioral and Brain Sciences (2018)

Abstract In the target article, Rahnev &amp; Denison (R&amp;D) use serial effects as an example of suboptimality. We show here that serial effects can be beneficial to perception, serving to reduce both error and response times in a near-optimal fashion. Furthermore, serial effects for stable attributes are positive, whereas those for changeable attributes are negative, demonstrating that they are engaged flexibly to optimize performance.
Identification of Two Early Life Eczema and Non-Eczema Phenotypes With High Risk For Asthma Development
Authors: Elisabet Johansson, Jocelyn M. Biagini Myers, Lisa J. Martin, Hua He, Patrick H. Ryan, Grace K. LeMasters, David I. Bernstein, James E. Lockey, Gurjit K. Khurana Hershey
Journal: Journal of Allergy and Clinical Immunology (2019)
Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042–2050
Authors: Lennart Tonneijck, Mark M. Smits, Marcel H.A. Muskiet, Trynke Hoekstra, Mark H.H. Kramer, A.H. Jan Danser, Piet M. ter Wee, Michaela Diamant, Jaap A. Joles, Daniel H. van Raalte
Journal: Diabetes Care (2019)

On page 2048 of the article cited above, the word “increases” was corrected to read “decreases.” The …
GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations
Authors: Paolo Sportoletti, Letizia Celani, Emanuela Varasano, Roberta Rossi, Daniele Sorcini, Chiara Rompietti, Francesca Strozzini, Beatrice Del Papa, Valerio Guarente, Giulio Spinozzi, Debora Cecchini, Oxana Bereshchenko, Torsten Haferlach, Maria Paola Martelli, Franca Falzetti, Brunangelo Falini
Journal: Leukemia (2019)
PTU-023 A review of endoscopic colorectal polypectomies performed across multiple centres in 2010 – are we adhering to bsg follow up guidance?
Authors: AM Verma, P Hooper, HL Lee, S Samani, S Kadri
Journal: Gut (2017)

Introduction  The BSG adenoma follow up (FU) guideline is widely recognised and implemented in Endoscopy practice. It is anecdotally noted that adherence to guideline is poor due to non-adenoma polypectomy and/or misinterpretation. This has significant clinical implications for patients and financial implications for the NHS. We aim to evaluate adherence to guideline by conducting a large multi-centre audit.  Method  1100+ polypectomies from 2010 (chosen as index year to allow evaluation of 5+ year FU intervals) performed at four endoscopy departments at University Hospitals Leicester and Kettering General Hospital NHS trusts, by a large number of operators, were analysed by interrogating endoscopy and histology reports and collated in a database, endoscopy FU intervals were compared to BSG guidance.  Results  FU data were discarded if not clear, terminated by clinician or confounded by other diseases. Overall 854 polypectomies were analysed. FU was classed as appropriate if performed  48 months for intermediate risk adenomas and 48–72 months for low risk adenomas.  Conclusion  There are potential confounders when interpreting the data; the guidance allows those with low risk adenomas to be discharged and upgrades FU for patients who have had high risk adenomas previously, also patient factors such as not being fit for FU and not wanting or attending FU. Adherence ranges from 62.31% for high risk adenomas to 11.85% of low risk adenomas, overall adherence to the guideline is only 32.44%. 44.03% alarmingly had no FU at all (range from 23.85% of high risk adenomas to 59.54% of low risk adenomas). Only 3.86% of FU was delayed. For intermediate and low risk adenomas, 23.20% of FU was performed too early.  The data suggests adherence to BSG guidance is suboptimal and could be improved with robust protocols of validation of referrals, and safeguards. The ramifications for patients with adenomas (especially high risk) without appropriate FU are increased morbidity and cancer. Poor compliance to the guideline has financial implications to a department when>20% of procedures are performed too early. Poor adherence is a greater problem in the symptomatic service as the bowel cancer screening programme FU is tightly regulated.  Reference  . SR Cairns, JH Scholefield, RJ Steele, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut2010;59:666–690.  Disclosure of Interest  None Declared
Abstract 11015: Why Don’t Heart Failure Patients Respond to Worsening Symptoms?
Authors: Chin-Yen Lin, Kathleen Dracup, Michele M Pelter, Martha J Biddle, Debra K Moser
Journal: Circulation (2015)

Background: Long delays in seeking medical care are common in patients with worsening symptoms of heart failure (HF) and lead to longer lengths of hospital stay, increased healthcare costs, and increased morbidity and mortality. However, patient-reported reasons for delay have rarely been explored. Objective: To describe patient-reported reasons for delay in seeking medical care for worsening symptoms. Methods: As part of a clinical trial designed to reduce HF readmission and mortality for worsening symptoms, we administered the HF Symptom Response Questionnaire to all patients prior to intervention. The instrument measures reasons why patients delay seeking treatment. All patients had a recent hospitalization for HF, were community dwelling in a rural location, and had no cognitive impairments as measured with the Mini-Cog. Results: A total of 614 HF patients (59% male, NYHA class III/IV 35%, 19% without a high school education, mean age 66±13 years, median b-type natriuretic peptide level 186 pg/ml [25th percentile = 72, 75th percentile = 462] were studied. The most common reasons for not seeking early treatment were symptom uncertainty (62.4%), symptoms seem vague or came on too gradually (67.4%), symptoms slightly different from last episode (55.2%) and the symptoms didn’t seem to be serious enough (62.2%). Other reasons include embarrassment at seeking treatment (23.9%), not wanting to second guess the doctor (21.7%), financial concerns (19.9%), transportation issues (16.4%), and other (10.7%). Reasons given in the other category included afraid/don’t like doctors or hospitals, care of pets at home, family needs them, not wanting to bother others, denial/don’t want to know/fear of knowing, and weather. Conclusions: Despite experiencing worsening HF symptoms of such intensity that hospitalization is required, most patients do not perceive that symptoms are intense or certain enough to warrant action. In many, treatment seeking decisions are superseded by factors not related to symptom appraisal such as family obligations, fear or denial, and embarrassment. Education to improve response to worsening HF symptoms requires skills in symptom appraisal, and counseling to overcome personal barriers to seeking treatment.
Early Subthreshold Aerobic Exercise for Sport-Related Concussion
Authors: John J. Leddy, Mohammad N. Haider, Michael J. Ellis, Rebekah Mannix, Scott R. Darling, Michael S. Freitas, Heidi N. Suffoletto, Jeff Leiter, Dean M. Cordingley, Barry Willer
Journal: JAMA Pediatrics (2019)

<h3>Importance</h3> Sport-related concussion (SRC) is a significant public health problem without an effective treatment. <h3>Objective</h3> To assess the effectiveness of subsymptom threshold aerobic exercise vs a placebo-like stretching program prescribed to adolescents in the acute phase of recovery from SRC. <h3>Design, Setting, and Participants</h3> This multicenter prospective randomized clinical trial was conducted at university concussion centers. Male and female adolescent athletes (age 13-18 years) presenting within 10 days of SRC were randomly assigned to aerobic exercise or a placebo-like stretching regimen. <h3>Interventions</h3> After systematic determination of treadmill exercise tolerance on the first visit, participants were randomly assigned to a progressive subsymptom threshold aerobic exercise or a progressive placebo-like stretching program (that would not substantially elevate heart rate). Both forms of exercise were performed approximately 20 minutes per day, and participants reported daily symptoms and compliance with exercise prescription via a website. <h3>Main Outcomes and Measures</h3> Days from injury to recovery; recovery was defined as being asymptomatic, having recovery confirmed through an assessment by a physician blinded to treatment group, and returning to normal exercise tolerance on treadmill testing. Participants were also classified as having normal (&lt;30 days) or delayed (≥30 days) recovery. <h3>Results</h3> A total of 103 participants were included (aerobic exercise: n = 52; 24 female [46%]; stretching, n = 51; 24 female [47%]). Participants in the aerobic exercise group were seen a mean (SD) of 4.9 (2.2) days after the SRC, and those in the stretching group were seen a mean (SD) of 4.8 (2.4) days after the SRC. There were no differences in age, sex, previous concussions, time from injury, initial symptom severity score, or initial exercise treadmill test and physical examination results. Aerobic exercise participants recovered in a median of 13 (interquartile range [IQR], 10-18.5) days, whereas stretching participants recovered in 17 (IQR, 13-23) days (<i>P</i> = .009 by Mann-Whitney test). There was a nonsignificant lower incidence of delayed recovery in the aerobic exercise group (2 participants [4%] in the aerobic group vs 7 [14%] in the placebo group;<i>P</i> = .08). <h3>Conclusions and Relevance</h3> This is, to our knowledge, the first RCT to show that individualized subsymptom threshold aerobic exercise treatment prescribed to adolescents with concussion symptoms during the first week after SRC speeds recovery and may reduce the incidence of delayed recovery. <h3>Trial Registration</h3> ClinicalTrials.gov identifier:NCT02710123
Chromobox Protein-7 (CBX7), a Polycomb Group Repressor, Functions as a Transcriptional Co-activator of Type 2 Cytokine Genes in Lymphoid Cells and is Important for Asthma
Authors: Kapil Sirohi, Mukesh Verma, Lidia Michalec, Anand Sripada, Jerome McKay, Donald Rollins, James Good, Magdalena M. Gorska, Richard J. Martin, Rafeul Alam
Journal: Journal of Allergy and Clinical Immunology (2019)
Low density lipoprotein receptor (LDLR) regulation by growth hormone in mesangial cells may be mediated by nitric oxide
Authors: M. O. Machado, J. Kariyil, G. H. Kim, D. F. Sellitti, J. Moore Jr., Rosario Dominguez Crespo Hirata, Mário Hiroyuki Hirata, P. Hirszel, Sonia de Quateli Doi
Journal: Journal of the American Society of Nephrology (1999)